Pfizer Stock To Go Ex-dividend Tomorrow (PFE)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for Pfizer (NYSE: PFE) is tomorrow, November 7, 2012. Owners of shares as of market close today will be eligible for a dividend of 22 cents per share. At a price of $24.59 as of 9:30 a.m. ET, the dividend yield is 3.6%.

The average volume for Pfizer has been 26.7 million shares per day over the past 30 days. Pfizer has a market cap of $183.38 billion and is part of the health care sector and drugs industry. Shares are up 13.4% year to date as of the close of trading on Monday.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. The company has a P/E ratio of 22.1, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Pfizer Ratings Report.

See our dividend calendar or top-yielding stocks list.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Profit With Technical Analysis: Cramer's 'Mad Money' Recap (Tuesday 2/20/18)

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

With the Correction In Pfizer Behind Us, Traders Can Go Long Again

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign